Women’s Health Diagnostics Market worth $36.6 billion by 2025 | CAGR: 7.6%

Posted June 28, 2022 by johnnyandrew

The global Women’s Health Diagnostics market has been segmented, on the basis of applications, and end users
The diagnosis and treatment of problems and diseases that may impair the physical and mental health of women is referred to as women's health diagnostics. Gynecology disorders, breast cancer, ovarian cancer, birth control, sexually transmitted infections (STIs), female cancers, menopause, hormone therapy, pregnancy and childbirth, sexual health, osteoporosis, heart disease, and benign conditions that may affect the functions of a female body are among the specialties and focus areas of the field.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=128928901

[270 Pages Report] The women’s health diagnostics market is projected to reach USD 36.6 billion by 2025 from USD 25.0 billion in 2020, at a CAGR of 7.9% during the forecast period.

This market is mainly driven by the increased adoption of point-of-care & rapid diagnostic tests, growth in the number of private diagnostic centers, high prevalence of infectious diseases in women, rising incidence of chronic & lifestyle-related disorders in women and increasing awareness about fertility testing in women & initiatives taken by government and health organizations.

In 2015, the breast cancer testing segment accounted for the largest share of the market. However, the prenatal genetic screening and carrier testing segment is expected to grow at a higher CAGR during the forecast period. This growth can be attributed to factors such as the growing number of doctors offering genetic screening tests to pregnant women and growing awareness about these tests.

The breast cancer testing segment accounts for the largest share of the market, by application, in 2019

Based on application, the women’s health diagnostics market is divided into nine segments—osteoporosis testing, OVC testing, cervical cancer testing, breast cancer testing, pregnancy & fertility testing, prenatal genetic screening & carrier testing, infectious disease testing, STD testing, and ultrasound tests. The breast cancer testing segment accounted for the larger market share in 2019. The large share of this segment can be attributed to the increasing incidence of breast cancer and rising awareness about advanced breast cancer diagnostic techniques, such as ABUS.

The home care settings segment is expected to grow at the highest CAGR during the forecast period

Based on end users, the women’s health diagnostics market is segmented into hospitals & clinics, diagnostic & imaging centers, and home care settings. The home care settings segment is expected to witness the highest growth during the forecast period. The increasing advantages of using self-testing kits will continue to drive market growth. Patient self-testing enables patients to better manage their diseases by utilizing home/self-testing kits. Technological advancements have made many self-testing kits available for various conditions, such as pregnancy and ovulation.

Geographical growth scenario of Women’s Health Diagnostics Market :

Geographically, the global market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. In 2015, North America commanded the largest share of the global women health diagnostics market. The major share of this region can be attributed to increasing prevalence of cancer among women in this region, increasing incidence of lifestyle related health disorders, growing focus of manufacturers of women’s health diagnostic products on expanding their presence in this region, and increasing demand for fertility testing monitors.

Leading market players and strategies adopted

The prominent players in this market are Siemens AG (Germany), Quest Diagnostics Inc. (U.S.), Hologic, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), PerkinElmer Inc. (U.S.), Alere Inc. (U.S.), GE Healthcare (U.S.), Becton, Dickinson and Company (BD) (U.S.), Abbott Laboratories (U.S.), bioMérieux SA (France), and Koninklijke Philips N.V. (Netherlands).

Recent Developments

Hoffmann-La Roche Ltd. Launched the uPath HER2 (4B5) Image Analysis and uPath Dual ISH Image Analysis.
Hologic, Inc. acquired Biotheranostics, a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, to strengthen its presence in the women’s health diagnostics market.
Hologic, Inc. launched the 3DQuorum Imaging Technology in Europe.
Carestream Health, Inc. opened a new global business operations center in Mumbai, India, expanding its market presence.

Frequently Asked Questions (FAQs) :

Which are the top industry players in the global women’s health diagnostics market?

Which global women’s health diagnostics appications have been included in this report?

Which geographical region is dominating in the global women’s health diagnostics market?

Which is the leading global women’s health diagnostics end user segment?
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By johnny
Country United States
Categories Blogging
Tags womens health diagnostics market
Last Updated June 28, 2022